C4 Therapeutics, Inc. Operating Income
C4 Therapeutics, Inc. (CCCC) reported Operating Income of -$26.42 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-11
- C4 Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$26.42M.
- C4 Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$27.79M.
- C4 Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$23.14M.
- C4 Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$34.41M.
- C4 Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$115.22M.
- C4 Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$119.61M.
- C4 Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$139.03M.
- C4 Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$129.53M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$26.42M 10-Q · filed 2026-08-11 | -$54.21M 10-Q · filed 2026-08-11 | -$77.35M derived: sum of 3 quarters · filed 2026-08-11 | -$111.77M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$27.79M 10-Q · filed 2026-05-12 | -$50.93M derived: sum of 2 quarters · filed 2026-05-12 | -$85.34M derived: sum of 3 quarters · filed 2026-05-12 | -$113.84M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$23.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$57.56M derived: sum of 2 quarters · filed 2026-02-26 | -$86.06M derived: sum of 3 quarters · filed 2026-08-11 | -$115.22M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$34.41M 10-Q · filed 2025-11-06 | -$62.91M derived: sum of 2 quarters · filed 2026-08-11 | -$92.08M 10-Q · filed 2025-11-06 | -$129.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$28.50M 10-Q · filed 2026-08-11 | -$57.66M 10-Q · filed 2026-08-11 | -$95.37M derived: sum of 3 quarters · filed 2026-08-11 | -$123.62M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$29.16M 10-Q · filed 2026-05-12 | -$66.87M derived: sum of 2 quarters · filed 2026-05-12 | -$95.12M derived: sum of 3 quarters · filed 2026-05-12 | -$116.56M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$37.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$65.95M derived: sum of 2 quarters · filed 2026-02-26 | -$87.39M derived: sum of 3 quarters · filed 2026-02-26 | -$119.61M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$28.24M 10-Q · filed 2025-11-06 | -$49.69M derived: sum of 2 quarters · filed 2025-11-06 | -$81.91M 10-Q · filed 2025-11-06 | -$119.33M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$21.44M 10-Q · filed 2025-08-07 | -$53.66M 10-Q · filed 2025-08-07 | -$91.09M derived: sum of 3 quarters · filed 2025-08-07 | -$118.90M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$32.22M 10-Q · filed 2025-05-07 | -$69.65M derived: sum of 2 quarters · filed 2025-05-07 | -$97.45M derived: sum of 3 quarters · filed 2025-05-07 | -$135.02M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$37.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$65.23M derived: sum of 2 quarters · filed 2025-02-27 | -$102.80M derived: sum of 3 quarters · filed 2025-02-27 | -$139.03M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$27.81M 10-Q · filed 2024-10-31 | -$65.38M derived: sum of 2 quarters · filed 2024-10-31 | -$101.60M 10-Q · filed 2024-10-31 | -$139.90M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | -$37.57M 10-Q · filed 2024-08-01 | -$73.80M 10-Q · filed 2024-08-01 | -$112.09M derived: sum of 3 quarters · filed 2024-08-01 | -$144.58M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$36.23M 10-Q · filed 2024-05-08 | -$74.52M derived: sum of 2 quarters · filed 2024-05-08 | -$107.01M derived: sum of 3 quarters · filed 2024-05-08 | -$134.39M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$38.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$70.78M derived: sum of 2 quarters · filed 2024-02-22 | -$98.17M derived: sum of 3 quarters · filed 2024-02-22 | -$129.53M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$32.49M 10-Q · filed 2023-11-01 | -$59.87M derived: sum of 2 quarters · filed 2023-11-01 | -$91.24M 10-Q · filed 2023-11-01 | -$106.50M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | -$27.38M 10-Q · filed 2023-08-08 | -$58.75M 10-Q · filed 2023-08-08 | -$74.01M derived: sum of 3 quarters · filed 2023-08-08 | -$98.26M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$31.37M 10-Q · filed 2023-05-04 | -$46.62M derived: sum of 2 quarters · filed 2023-05-04 | -$70.88M derived: sum of 3 quarters · filed 2023-05-04 | -$92.99M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$15.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$39.51M derived: sum of 2 quarters · filed 2023-02-23 | -$61.63M derived: sum of 3 quarters · filed 2023-02-23 | -$82.13M 10-K · filed 2023-02-23 |
| 2021-09-30 | -$24.25M 10-Q · filed 2022-11-03 | -$46.37M derived: sum of 2 quarters · filed 2022-11-03 | -$66.88M 10-Q · filed 2022-11-03 | -$85.78M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$22.12M 10-Q · filed 2022-08-04 | -$42.63M 10-Q · filed 2022-08-04 | -$61.53M derived: sum of 3 quarters · filed 2022-08-04 | -$79.88M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | -$20.51M 10-Q · filed 2022-05-05 | -$39.41M derived: sum of 2 quarters · filed 2022-05-05 | -$57.76M derived: sum of 3 quarters · filed 2022-05-05 | -$68.62M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | -$18.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$37.25M derived: sum of 2 quarters · filed 2022-02-24 | -$48.11M derived: sum of 3 quarters · filed 2022-02-24 | -$60.45M 10-K · filed 2022-02-24 |
| 2020-09-30 | -$18.35M 10-Q · filed 2021-11-10 | -$29.21M derived: sum of 2 quarters · filed 2021-11-10 | -$41.55M 10-Q · filed 2021-11-10 | -$52.05M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | -$10.86M 10-Q · filed 2021-08-11 | -$23.20M 10-Q · filed 2021-08-11 | -$33.70M derived: sum of 3 quarters · filed 2022-02-24 | -$43.70M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$12.34M 10-Q · filed 2021-05-13 | -$22.84M derived: sum of 2 quarters · filed 2022-02-24 | -$32.84M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | -$10.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | -$20.50M derived: sum of 2 quarters · filed 2022-02-24 | -$35.45M 10-K · filed 2022-02-24 | |
| 2019-09-30 | -$10.00M 10-Q · filed 2020-11-12 | -$24.95M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |